Kazakhstan, Russia, Ukraine to change drug reimbursement schemes

Home/Policies & Legislation | Posted 24/05/2013 post-comment0 Post your comment

Most of the Commonwealth of Independent States (CIS) countries do not have modern drug reimbursement policies. However, recently Kazakhstan, Russia and Ukraine have all taken steps to improve their drug policies and introduce drug reimbursement schemes similar to those employed in other countries.

CIS emblem V13E24

If introduced, these could completely change the operating environment for both the generic and originator drug markets in these countries. Presently, the rate of growth of originator medicines in CIS countries is lower than that of their generics counterparts.

In Kazakhstan, the lists of reimbursed drugs have been updated (increasing by 40% the number of medicines available free of charge) and a new reimbursement model is being created. This should result in patients who previously paid 50% of the cost of medicines now obtaining them free of charge. In Russia, the Pharma 2020 plan is being implemented in order to improve the quality and accessibility of locally produced drugs. This is expected to result in an effective drug reimbursement system by 2025. Ukraine, on the other hand, has implemented a pilot programme for reference pricing, which involved the introduction of state regulation of the prices of hypertension medicines, along with partial reimbursement of the cost from the state and local budgets.

Currently, the growth rate for originator medicines in these CIS countries is lower than for generics; during 2012 the originator market increased by 10% to almost Euros 6 billion at wholesale prices, while generics grew by 16% to Euros 5.7 billion, according to the latest report from research and consulting company PMR.

The changes are expected to fuel growth in the generics sector, as well as increase the market for originator drugs. Compound annual growth rates (CAGRs) for generics and originator markets are expected to be 15% and 14%, respectively, between 2012 and 2014.

Related article

Russian drug spending set to reach US$4 billion by 2020

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
United States legislation to improve access to insulin
Insulin 1 V13C03
Home/Policies & Legislation Posted 29/04/2022
Nomenclature of biologicals and biosimilars in Chile
Home/Policies & Legislation Posted 22/04/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010